GCG and macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss: Accordingly, GLP-2 has been studied in patients with short bowel syndrome (SBS) (70) and, since 2012, a DPP-4 resistant GLP-2 analog (teduglutide) has been used in the treatment of SBS.